Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Toxicity Clear all
Completed Not applicable Interventional Results available

Characterizing and Addressing Financial Toxicity in AYAs With Cancer

NCT06072833
View directory record Official record
Conditions
Cancer in Adolescence
Interventions
Patient Financial Education / Navigation
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
15 Years to 39 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Nikkomycin Z in Healthy Subjects

NCT00834184
View directory record Official record
Conditions
Healthy
Interventions
nikkomycin Z
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
View directory record Official record
Conditions
Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
Interventions
cefixime, irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 22, 2026, 5:53 AM EDT
Active, not recruiting Phase 1 Interventional

'ADVANCE' (A Pilot Trial)

NCT03858322
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Cyclophosphamide, Carboplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Milford, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Withdrawn No phase listed Observational

Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity

NCT02469194
View directory record Official record
Conditions
Severe or Mild Toxicity From Radiotherapy and/or Chemotherapy
Interventions
Blood Draw
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Not applicable Interventional

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

NCT05197881
View directory record Official record
Conditions
Cervical Cancer by FIGO Stage 2018
Interventions
Varian Ethos Adaptive Radiation Therapy
Device
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
5
States / cities
Burmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Pre-dive Ketone Food Products on Latency to CNS Oxygen Toxicity (Aim 2)

NCT05831228
View directory record Official record
Conditions
Oxygen Toxicity
Interventions
Ketogenic food products, Control: Placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

MR Image Guided Therapy in Prostate Cancer

NCT01377753
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Visualase Thermal Therapy System
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional

Out of Pocket Cost Communication in Multiple Sclerosis Patients

NCT04257071
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Usual Care, OOP Cost Communication and Optimization
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jul 22, 2026, 5:53 AM EDT
Completed No phase listed Observational

Case-Control Viramune (Nevirapine) Toxicogenomics Study

NCT00310843
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Baltimore, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Public Health Initiative on Alcohol Flushing

NCT06397716
View directory record Official record
Conditions
Alcohol Toxicity
Interventions
ALDH2 Genotyping
Genetic
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed No phase listed Observational

Machine Learning to Predict Acute Care During Cancer Therapy

NCT05122247
View directory record Official record
Conditions
Chemotherapeutic Toxicity
Interventions
Machine learning algorithm
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Early Phase 1 Interventional

AvenovaTM as a Sterile Skin Preparation Agent

NCT02990013
View directory record Official record
Conditions
Cleaning Product Causing Toxic Effect
Interventions
Avenova, Povidone-iodine 5% solution, 4% chlorhexidine, Isopropyl alcohol
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 5:53 AM EDT
Terminated Phase 4 Interventional Results available

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00754767
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
Interventions
L-carnitine L-tartrate, placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Not applicable Interventional

Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy

NCT07073807
View directory record Official record
Conditions
Cancer, Neoplasms
Interventions
SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Irvine, California • Newport Beach, California • Orange, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Withdrawn Phase 2 Interventional

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

NCT00003407
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Chicago, Illinois • Kankakee, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 22, 2026, 5:53 AM EDT
Active, not recruiting Not applicable Interventional

Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer

NCT02517034
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
5
States / cities
Duarte, California • Lancaster, California • Rancho Cucamonga, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Eribulin in HER2 Negative Metastatic BrCa

NCT01827787
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Milford, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003144
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

NCT01856543
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Eucerin, Mometasone Furoate 0.1%
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Jul 22, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products

NCT03492463
View directory record Official record
Conditions
Nicotine Dependence, Cigarettes
Interventions
Nicotine patch, Placebo patch, E-cigarettes, Non-nicotine e-cigarettes
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

NCT04084730
View directory record Official record
Conditions
Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1, DCIS Grade 2, Breast Cancer
Interventions
Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Norwalk, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 5:53 AM EDT